How the insurance industry denies claims; consumers confused by complexity and red tape; and how the ALS drug Relyvrio came to be.
UnitedHealthcare Tried to Deny Coverage to a Chronically Ill Patient. He Fought Back, Exposing the Insurer’s Inner Workings.
Data show that insurers reject about 1 in 7 claims for treatment. One family’s fight for coverage for treatment for ulcerative colitis shows the inner workings of UnitedHealthcare’s procedures for denying claims, according to a story published by ProPublica. Although the insurer claimed the high cost of biologics used to treat this patient’s ulcerative colitis didn’t factor into its denial, recordings of conversations and other documents show that cost was top of mind for those making decisions at United.
How Often Do Health Insurers Say No to Patients? No One Knows.
Another article published by ProPublica looks into insurer companies’ denial rates. Done in collaboration with The Capitol Forum, this review finds there is a lack of transparency about denial rates. Some suggest that between 10% and 20% of claims are denied, but there is limited data and rates vary from plan to plan and across services.
KFF Survey of Consumer Experiences with Health Insurance
Most (58%) people with health insurance say they encountered at least one problem using their coverage in the past year, finds a new KFF survey of consumer experiences with health insurance. About half of insured adults report some difficulty understanding at least one aspect of their health insurance, such as what their insurance will cover (36%), what they will owe out-of-pocket for care (30%), or what their explanation of benefits statement means (30%).
When Dying Patients Want Unproven Drugs
A story in the New Yorker looks at how AIDS activists fighting for access to experimental drugs led to the accelerated approval process and new treatments for ALS. The story interviews ALS patients, doctors, advocates and the two then-college students who had the idea for the recently approved Relyvrio.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More